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Background: HIV-1 transcription is activated by the viral Tat protein that recruits host positive transcription
elongation factor-b (P-TEFb) containing CDK9/cyclin T1 to the HIV-1 promoter. P-TEFb in the cells exists as a lower
molecular weight CDK9/cyclin T1 dimer and a high molecular weight complex of 7SK RNA, CDK9/cyclin T1, HEXIM1
dimer and several additional proteins. Our previous studies implicated CDK2 in HIV-1 transcription regulation. We
also found that inhibition of CDK2 by iron chelators leads to the inhibition of CDK9 activity, suggesting a functional
link between CDK2 and CDK9. Here, we investigate whether CDK2 phosphorylates CDK9 and regulates its activity.
Results: The siRNA-mediated knockdown of CDK2 inhibited CDK9 kinase activity and reduced CDK9
phosphorylation. Stable shRNA-mediated CDK2 knockdown inhibited HIV-1 transcription, but also increased the
overall level of 7SK RNA. CDK9 contains a motif (90SPYNR94) that is consensus CDK2 phosphorylation site. CDK9 was
phosphorylated on Ser90 by CDK2 in vitro. In cultured cells, CDK9 phosphorylation was reduced when Ser90 was
mutated to an Ala. Phosphorylation of CDK9 on Ser90 was also detected with phospho-specific antibodies and it
was reduced after the knockdown of CDK2. CDK9 expression decreased in the large complex for the CDK9-S90A
mutant and was correlated with a reduced activity and an inhibition of HIV-1 transcription. In contrast, the
CDK9-S90D mutant showed a slight decrease in CDK9 expression in both the large and small complexes but
induced Tat-dependent HIV-1 transcription. Molecular modeling showed that Ser 90 of CDK9 is located on a flexible
loop exposed to solvent, suggesting its availability for phosphorylation.
Conclusion: Our data indicate that CDK2 phosphorylates CDK9 on Ser 90 and thereby contributes to HIV-1
transcription. The phosphorylation of Ser90 by CDK2 represents a novel mechanism of HIV-1 regulated transcription
and provides a new strategy for activation of latent HIV-1 provirus.Background
Despite efficient anti-retroviral therapy, eradication of
HIV-1 infection is challenging and requires novel bio-
logical insights and therapeutic strategies. Eradication of
latent HIV-1 provirus is especially challenging as inte-
grated HIV-1 is not affected by the existing anti-HIV-1
drugs until its transcription is activated [1]. HIV-1 tran-
scription from HIV-1 LTR depends on both host cell fac-
tors and the HIV-1 transactivation Tat protein [2]. While* Correspondence: snekhai@howard.edu
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reproduction in any medium, provided the orlatency is mostly studied on HIV-1 subtype B, other HIV-
1 subtypes have different configuration of HIV-1 LTR that
may determine transcription activity of the integrated pro-
virus [3]. In a model of acute HIV-1 infection, HIV-1 sub-
types A, B, C, D, F and AG had similar latency profiles
while subtype AE showed a reduced potential for latency,
which correlated with the presence of GABP instead of
NF-κB transcription factor binding site in the LTR [3].
Major function of HIV-1 Tat protein is to recruit the posi-
tive transcription elongation factor b (P-TEFb), that con-
tains the cell cycle-dependent kinase (CDK) 9 and cyclin
T1 to the TAR RNA, a hairpin-loop structure located at
the 50-end of all nascent HIV-1 transcripts [4]. The HIV-1
TATA box and its flanking regions are recognized by the
cellular pre-initiation complexes that require CTGCLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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TAR RNA that may contribute to the establishment of la-
tency [5]. Nucleosomal structure of integrated HIV-1 pro-
virus may also contribute to the establishment of HIV-1
latency. HIV-1 chromatin-associated Spt6 maintains chro-
matin structure in the wake of RNAPII and is protected
by Proteasomal ATPase-associated factor 1 (PAAF1) from
proteasomal degradation [6]. Knockdown of either Spt6 or
PAAF1 leads to the loss of histones from HIV-1 genomic
DNA and production of transcripts defective for protein
synthesis [6]. P-TEFb in the cells exists in two molecular
weight forms. The lower molecular weight kinase active
form of P-TEFb consists of CDK9 and cyclin T1 [7,8]. The
high molecular weight inactive form of P-TEFb contains
7SK RNA, a dimer of CDK9/cyclin T1 and several add-
itional proteins including HEXIM1 dimer, La-related
LARP7 protein [9-11] and the methylphosphatase capping
enzyme MePCE [12,13]. HEXIM1 binds with its inhibitory
PYNT sequence to the active site of CDK9 [14]. The high
molecular weight complex plays an important role in the
activation of HIV-1 transcription, as it serves as a source
of P-TEFb for the recruitment by HIV-1 Tat [15]. The im-
portance of the CDK9 component of the large form of P-
TEFb has been demonstrated by the effect of the CDK9
inhibitors, flavopiridol and DRB, which reduce the amount
of the large form of P-TEFb and inhibit HIV-1 replication
[16]. HIV-1 Tat protein was recently shown to recruit P-
TEFb to HIV-1 pre-initiation complex in inactive form
along with 7SK RNA and that formation of TAR RNA can
displace 7SK RNA [17]. Tat was also shown to facilitate
the formation of super-elongation complex (SEC) contain-
ing active P-TEFb and additional elongation factors and
co-activators [18,19]. P-TEFb triggers elongation of RNA
polymerase II (RNAPII) transcription by phosphorylating
the negative elongation factor (NELF) and the DRB-
sensitivity inducing complex (DSIF/Spt4/Spt5), which pro-
motes the release of NELF [20]. P-TEFb also phosphory-
lates the Ser-2 residues of the C-terminal domain (CTD)
of the largest subunit of RNA Polymerase II (RNAPII).
Our previous studies also implicated CDK2 in the regula-
tion of HIV-1 transcription [21,22]. The knock-down of
CDK2 inhibited HIV-1 transcription and replication [23].
CDK2 was found to associate with the HIV-1 promoter
in vitro [21] and in vivo [24]. Inhibition of CDK with small
molecule inhibitor roscovitin [25], inhibited HIV-1 replica-
tion and prevented the association of CDK2 with the HIV-
1 promoter [24]. Roscovitin and its analog CR8, also inhib-
ited CDK9 activity [16], suggesting that CDK2 and CDK9
might be functionally linked [26,27]. Further support for
this functional link came from the observation that inhib-
ition of CDK2 by iron chelators inhibited CDK9 activity
and HIV-1 transcription [28,29]. CDK9 has at least ten
phosphorylation sites. Phosphorylation of Thr186 is crit-
ical for the activity of CDK9 [30,31] and the association ofCDK9/cyclin T1 with 7SK RNA snRNP [30,31]. Autopho-
sphorylation of Thr29 [32] and the C-terminal residues
Ser329, Thr330, Thr333, Ser334, Ser347, Thr350, Ser353,
and Thr354 [30] has also been reported. We recently
showed that dephosphorylation of the T-loop Ser 175 resi-
due by protein phosphatase-1 induces CDK9 activity and
activates HIV-1 transcription [33].
Here, we investigated the phosphorylation of CDK9 by
CDK2, using a siRNA and shRNA-mediated knockdown
approach. We identified Ser 90 of CDK9 as a novel and
key CDK2 phosphorylation site, and analyzed its effect
on the distribution of P-TEFb between large and small
molecular weight complexes and the ability of CDK9 to
activate HIV-1 transcription. We also modeled Ser90 in
the CDK9 structure.
Results
The transient knockdown of CDK2 by siRNA inhibits CDK9
activity
Previously, we utilized siRNA-mediated CDK2 knock-
down (KD) to demonstrate the importance of CDK2 for
HIV-1 transcription [23]. Here, we analyzed the effect of
CDK2 KD on CDK9 activity and phosphorylation. 293T
cells were transiently transfected with CDK2-targeted
siRNA or a control siRNA that resulted in the inhibition
of CDK2 expression but had no effect on the expression
of endogenous CDK9 and cyclin T1 or tubulin
(Figure 1A, lanes 1 and 2). To measure CDK9 activity,
the siRNA-transfected cells were co-transfected with
Flag-tagged CDK9 and cyclin T1, and CDK9 was immu-
noprecipitated with anti-Flag antibodies. Expression of
Flag- CDK9 was not affected by CDK2 KD (Figure 1B,
upper panel). CDK9 activity, analyzed with GST-CTD as
a substrate, was reduced in the cells transfected with
CDK2-targeted siRNA but not in the cells transfected
with control siRNA (Figure 1B, middle panel, lanes 1
and 2). These results suggest that the transient inhibition
of CDK2 has a negative effect on CDK9 activity.
The loss of CDK2 inhibits CDK9 phosphorylation
Because CDK9 kinase activity is regulated by phosphor-
ylation [30-32], we analyzed the overall level of CDK9
phosphorylation in the cells transfected with CDK2-
directed siRNA. The siRNA-transfected 293T cells were
re-transfected with Flag-tagged CDK9 and then treated
with (32P) orthophosphate to allow CDK9 phosphoryl-
ation. CDK9 was precipitated with anti-Flag antibodies
from the cellular lysates, and CDK9 phosphorylation
was analyzed by Phosphor Imaging. CDK9 phosphoryl-
ation was reduced in the cells transfected with CDK2-
targeted siRNA in comparison to the control siRNA
(Figure 1C, lanes 2 and 3) suggesting that the inhibition
of CDK2 reduces the overall level of CDK9 phosphoryl-
ation. Because CDK9 activity is regulated by Thr186
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Figure 1 Inhibition of CDK9 activity and phosphorylation by CDK2-directed siRNA. (A-B) Inhibition of CDK2 expression and CDK9 activity.
Lysates from 293T cells transfected with CDK2-directed (lane 1) or control siRNA (lane 2) were analyzed by immunoblotting for the expression of
CDK2, CDK9, cyclin T1 and tubulin (panel A)Panel B, the cells were also co-transfected with Flag-CDK9 and cyclin T1 expression vectors. Lysates
were immunoblotted with antibodies against CDK2, Flag and α-tubulin as loading control (upper panel) or immunoprecipitated with anti-Flag
antibodies (lanes 1 and 2) or non-specific IgGs (lane 3) (lower panel). CDK9 activity was analyzed with GST-CTD as substrate. Lane 4, control
recombinant CDK9/cyclin T1. GST-CTD is shown as Coomassie stain. Quantification is shown as average from three independent experiments.
(C) Inhibition of CDK9 phosphorylation. Lysates from 293T cells transfected with CDK2-directed (lane 3) or control siRNA (lanes 1 and 2) and also
with a vector expressing Flag-CDK9 WT as in panel B then pulse-labeled with (32P) were immunoprecipitated with anti-Flag antibodies (lanes 2
and 3) or with non-specific IgGs (lane 1), resolved on 10% SDS PAGE and exposed to a Phosphor imaging device (upper panel) or analyzed by
immunoblotting with anti-CDK9 antibodies (lower panel). (D) No effect on CDK9 Thr186 phosphorylation. Lysates from 293T cells transfected
CDK2-directed (lane 1) or control siRNA (lanes 2 and 3) and then co-transfected with vectors expressing Flag-CDK9 WT (lanes 1 and 2) or Flag-
CDK9 T186A (lane 3) were immunoprecipitated with anti-Flag antibodies and analyzed by immunoblotting with Thr186 phospho-specific or anti-
CDK9 antibodies.
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ylation in the cells transfected with CDK2-directed
siRNA. Flag-tagged WT CDK9 and CDK9 T186A mu-
tant were co-transfected into the siRNA transfected
cells. CDK9 was precipitated with anti-FLAG antibodies,
and Thr186 phosphorylation was analyzed with
phospho-specific antibodies. Phosphorylation of Thr186
was similar in the cells transfected with CDK2-directed
siRNA and the cells transfected with control siRNA
(Figure 1D, lanes 1 and 2), suggesting that CDK2 knock-
down has no effect on Thr186 phosphorylation. The
specificity of the antibodies was confirmed with the
CDK9 T186A mutant, which showed no Thr186 phos-
phorylation (Figure 1D, lane 3). These results suggest
that CDK KD has a negative effect on overall CDK9
phosphorylation which was not related to Thr186
phosphorylation.The stable knockdown of CDK2 inhibits HIV-1
Transcription
To further analyze the effect of CDK2 inhibition on HIV-1
transcription, we first generated stable cell lines that ex-
press CDK2-targeting shRNAs using vectors that target
several distinct sequences of CDK2 (see Experimental Pro-
cedures). Only 293T cells expressing the shRNA that tar-
geted the 1010atggacggagcttgttatc1028 sequence (OS211959)
showed about 40% reduction of CDK2 mRNA (Figure 2A,
CDK2; 293T-CDK2 KD). In contrast, no significant
change was observed for cyclin A mRNA expression
(Figure 2A). Interestingly, cyclin E mRNA expression level
was increased in 293T-CDK2 KD cells (Figure 2A). Cell
cycle analysis of the 293T-CDK2 KD cells by FACS
showed no significant difference in comparison to the par-
ental 293T cells (Figure 2B), suggesting that a partial
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Figure 2 CDK2 KD inhibits HIV-1 transcription. (A) Expression of CDK2 mRNA is reduced in CDK2 KD cells. Total RNA was extracted from 293T
cells and 293T-CDK KD cells lysates, reverse transcribed and analyzed by real-time PCR. β-Actin was used as an internal control. Quantification is
shown in triplicates. (B) Cell cycle analysis of 293T-59 cells. Cells were fixed with 70% ethanol, stained with Propidium Iodine and analyze by
FACS. Quantification is shown in triplicates. (C) CDK2 protein expression is reduced in 293T-CDK KD cells. Lysates from 293T and 293T-CDK2 KD
cells (lanes 1 and 2) were analyzed for CDK2 expression by western blotting. Quantification is shown for three independent experiments.
(D) Inhibition of VSVG HIV-1 Luc replication. 293T and 293T-CDK2-KD cells were infected with VSVG-pNL4-3 Luc virus and luciferase activity was
measured. MTT assay was used for the normalization. Quantification is shown for three independent experiments. (E) CDK2 protein expression is
reduced in HeLa-CDK2 KD cells. CDK2, tubulin and CDK9 expression was analyzed in HeLa and HeLa-CDK2 KD cells (lanes 1 and 2) by western
blotting. (D) Inhibition of VSVG HIV-1 Luc replication. Lane1, CDK2 expression was analyzed in HeLa and HeLa-CDK2 KD cells by Real-time PCR.
18S RNA was used as an internal control. Quantification is shown in triplicates. Lane 2, Luciferase expression of VSVG-HIV-1 Luc was analyzed in
infected HeLa and HeLa -CDK2-KD cells at 48 hours post infection. MTT assay was performed for the normalization. Quantification is shown for
three independent experiments.
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expression showed about 40% reduction in CDK2 expres-
sion in 293T-CDK2 KD cells (Figure 2C, lane 2).
To analyze the effect of stable CDK2 knock-down on
HIV-1 transcription, 293T-CDK2 KD cells were infected
with VSVG-pseudotyped pNL-4-3 Luc, which expresses
luciferase in place of nef. For normalization, MTT assay was
used. Luciferase activity was significantly reduced in 293T-
CDK2 KD cells compared to 293T cells (Figure 2D), sug-
gesting that reduction of CDK2 expression suppresses HIV-1 transcription. Similar results were obtained when 293T-
CDK KD cells were co transfected with an HIV-1 genomic
clone, pNL-4-3 Luc that expresses luciferase in place of nef
and CMV-Lac Z vector which showed reduction of lucifer-
ase normalized to β-galactosidase activity in 293T-CDK2
KD cells compared to 293T cells (data not shown). We also
generated HeLa CDK2 KD cell line, which showed reduced
CDK2 protein expression (Figure 2E, lane 2) and CDK2
mRNA expression (Figure 2F, lane 1). Infection with VSVG-
HIV-1 Luc also showed reduced luciferase expression in
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gether, these results indicate that stable CDK2 KD inhibits
HIV-1 transcription and single round HIV-1 replication.
Stable CDK2 KD increases 7SK RNA levels
To analyze the expression of P-TEFb in the large and
small complexes of 293T-CDK2 KD cells, we initially
followed the protocol developed by David Price and his
colleagues [16] in which the large P-TEFb complex was
extracted during cell lysis with a buffer containing low
salt concentration, and the small complex was recovered
with subsequent extractions using a high-salt buffer.
Large and small complexes were extracted from 293T
and 293T-CDK2 KD cells. The low salt extraction con-
tained cytoplasmic proteins as evidenced by the presence
of eIF-2α protein (Figure 3A, lanes 1 and 3), whereas
nuclear proteins were extracted with high salt as evi-
denced by the presence of RNAPII (Figure 3A, lanes 2
and 4). HEXIM1 was extracted with low salt suggesting
the extraction of large P-TEFb complex (Figure 3A,
lanes 1 and 3). There was less CDK9 in the large com-
plex and more in small complex present in 293T-CDK2
KD cells in comparison to the 293T cells (Figure 3A and
B). Correspondingly, there was more cyclin T1 present
in the small complex in 293T-CDK2 KD cells
(Figure 3C). To further confirm that low salt extraction
reflected large P-TEFb complex, we analyzed the effect
of CDK9 inhibitor, ARC, on the presence of CDK9 in
the large complex because CDK9 inhibitors were shown
to reduce CDK9 association with the large P-TEFb com-
plex [16]. Treatment with 10 μM ARC significantly
reduced CDK9 in low salt but not in the high salt
extracts (Figure 3D), further confirming that low salt ex-
tract contains large P-TEFb complex. To further investi-
gate the association of CDK9 with the large P-TEFb
complex, we determined the amount of 7SK RNA asso-
ciated with P-TEFb in CDK2 KD cells. CDK9 was immu-
noprecipitated from 293T and 293T-CDK2 KD cells
lysates and the associated 7SK RNA was analyzed by
RT-PCR. A semiquantitative and quantitative RT-PCR
showed, unexpectedly, more 7SK RNA associated with
P-TEFb in 293T-CDK2 KD cells compared to 293T cells
(Figure 3E, upper and low panels correspondently).
However, total 7SK RNA levels were much higher in
293T KD cells (Figure 3F, lane 2). When we analyzed
7SK RNA in the low salt and high salt lysates, much
higher levels of 7SK RNA were found in the low salt
extracts from 293T-CDK2 KD cells compared to 293T
cells (Figure 3G, lanes 1 and 2). Smaller amounts of 7SK
RNA were found in the high slat lysates of 293T and
293T-CDK2 KD cells (Figure 3G, lanes 3 and 4). Thus,
because of this unexpected increase in the total amount
of 7SK RNA in 293T-CDK2 KD cells, we could not con-
clude with definition whether CDK9 phosphorylationhas a direct effect on the association with the large P-
TEFb complex.
CDK2 phosphorylates Serine 90 of CDK9
A typical CDK2-phosphorylation site contains the (S/T)
PX(K/R) sequence [34]. Analysis of the sequence of
CDK9 revealed the presence of a S90PYNR94, which
qualifies as a CDK2 consensus phosphorylation site. We
analyzed CDK9 phosphorylation by CDK2 using pep-
tides that span potential phosphorylation sites including
N-terminal Thr29; the T-loop Ser175 and Thr186; and
Ser90. CDK2 phosphorylated a peptide containing Ser90
(Figure 4A, lane 3) but not Thr29 or Ser175/Thr186
(Figure 4A, lanes 1 and 2).
We then analyzed whether CDK2 phosphorylates
CDK9 Ser90 in the whole CDK9 protein in vitro. Flag-
tagged WT CDK9 and CDK9 S90A mutants were
expressed in 293T cells, immunoprecipitated with anti-
FLAG antibodies and subjected to phosphorylation with
recombinant CDK2/cyclin E. Phosphorylation of the
CDK9 S90A mutant was reduced (Figure 4B, lane 2) in
comparison to the phosphorylation of WT CDK9
(Figure 4B, lane 1), suggesting that CDK2 phosphory-
lates Ser90.
We next analyzed whether Ser90 can be phosphory-
lated in cultured cells. WT CDK9, CDK9 S90A and
CDK9 S90D mutants were expressed in 293T cells. The
cells were incubated in phosphate-free media and then
treated with (32P) orthophosphate. CDK9 was immuno-
precipitated with anti-FLAG antibodies and resolved on
SDS-PAGE. CDK9 phosphorylation was analyzed with
the Phosphor Imager. Both the S90A and S90D substitu-
tions reduced CDK9 phosphorylation (Figure 4C, lanes 2
and 3), as compared to the phosphorylation of WT
CDK9 (Figure 4C, lane 1), suggesting that CDK9 Ser90
is phosphorylated in vivo.
The phosphorylation of CDK9 on Ser90 was further
investigated with Ser90 phospho-specific antibodies. The
specificity of the antibodies was confirmed with the
CDK9 S90A mutant, which showed no phosphorylation
(Figure 4D compare lanes 1 and 2). The phosphorylation
of CDK9 on Ser90 was decreased in the CDK2 KD cells
(Figure 4E, compare lanes 1 and 2), suggesting that
CDK2 KD affected Ser90 phosphorylation. Together,
these results showed that CDK2 phosphorylates CDK9
on Ser90.
Mutation of Ser90 alters the association of CDK9 with the
large P-TEFb complex
To analyze the effect of Ser90 phosphorylation on the
association of CDK9 and cyclin T1 with the large and
small molecular weight complexes, 293T cells were
transfected with WT CDK9, the non-phosphorylatable
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Figure 3 Stable expression of CDK2-directed shRNA induces 7SK RNA expression. (A-C) Effect of CDK2 KD on small and large P-TEFb
complexes. Lysates from 293T and 293T-CDK2 KD cells sequentially extracted with low and high salt buffers, were analyzed by immunoblotting
for CDK9, cyclin T1, Hexim 1, eIF-2α and RNAPII. Panels B and C show average results from three experiments. (D) CDK9 inhibitor ARC prevents
CDK9 with association with large P-TEFb complex. Lysates from 293T cells untreated or treated with 10 μM ARC and extracted with low salt
buffer (10 mM) or high salt buffer (450 mM) were resolved on 10% SDS-PAGE and analyzed by immunoblotting for CDK9 and tubulin. Average
CDK9 expression adjusted to tubulin from two separate experiments is shown. (E) CDK2 KD increases the amount of 7SK RNA associated with
CDK9. RNA isolated from co-immunoprecipitates with anti-CDK9 antibodies or control IgGs from 239T or 293T-CDK2 KD whole cell lysates was
reverse transcribed and analyzed by semi-quantitative (30 cycles, upper panel) or real-time PCR (lower panel). Results are presented as numbers of
copies of 7SK RNA. (F) CDK2 KD increases total 7SK RNA amount. 7SK RNA was analyzed in whole cell lysates of 293T or 293T-CDK2 KD cells by
real-time PCR using 7SK expression vector as control. Results are presented as numbers of copies of 7SK RNA. (G) CDK2 KD increases 7SK RNA in
the large complex fraction. 7SK RNA was analyzed by real-time PCR using U6 RNA as reference. Quantification is shown in triplicates.
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T1. Analysis of CDK9 expression in the large and small
complexes showed a decrease of CDK9S90A in the large
P-TEFb complex but not the WT CDK9 or CDK9 S90D
(Figure 5A and B), suggesting that the CDK9 S90A mu-
tant is less efficiently associated with the large P-TEFb
complex. To further investigate the effect of CDK9 S90A
mutant, we analyzed co-precipitation of CDK9, cyclin
T1 and HEXIM1. CDK9 S90A mutant precipitated withabout 50% less HEXIM1 while binding equal amount of
cyclin T1 (Figure 5C, lane 3) suggesting that CDK9
S90A mutant less efficiently associated with the large P-
TEFb complex.
Ser90 of CDK9 affects HIV-1 transcription
We next analyzed the effect of Ser 90 mutations on
HIV-1 transcription. The 293T cells were transfected
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Figure 4 CDK2 phosphorylates Ser90 residue of CDK9. (A) CDK2 phosphorylates Ser90-containing peptide. CDK9-derived chemically
synthesized peptides containing Thr29; Ser175 and Thr186; or Ser90 residues were phosphorylated by recombinant CDK2/cyclin E and analyzed
by Phosphor Imaging Device (upper panel) or stained with Coomassie (lower panel). (B) CDK9 S90A mutant is less phosphorylated by CDK2/
cyclin E in vitro. WT CDK9 and CDK9 S90A were expressed in 293T cells, precipitated with anti-FLAG antibodies and incubated with recombinant
CDK2/cyclin E in the presence of (32P) ATP. The reactions were resolved on a 10% SDS Tris-glycine gel and analyzed by immunoblotting (upper
panel) or on Phosphor Imaging Device (lower panel). Quantification from the Phosphor Imager is shown. (C) Substitution of CDK9 Ser 90
prevents its phosphorylation in cultured cells. 293T cells transfected with FLAG-tagged WT CDK9, CDK9 S90A and CDK9 S90D and also co-
transfected with Cyclin T1, pulse-labeled with (32P) and CDK9 was immunoprecipitated from cellular lysates with anti-FLAG antibodies, and
analyzed by immunoblotting (upper panel) or by Phosphor Imaging Device (lower panel). Quantification of the bands on Phosphor Imager is
shown for three independent experiments. (D and E) CDK9 Ser90 phosphorylation is decreased in CDK2 KD cells. 293T cells were transfected
with vectors expressing Flag-CDK9 WT or Flag-CDK9 S175A (panel D); or 293T and 293T-59 cells were transfected with a vector expressing Flag-
CDK9 WT (panel E) and after 48 hrs in culture treated with 0.1 μM okadaic acid. CDK9 was immunoprecipitated with anti-Flag antibodies and
analyzed by immunoblotting with anti-CDK9 or Ser90 phospho-specific antibodies.
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LTR-Luc reporter and CMV-EGFP expressing vector
(for normalization). In the absence of Tat, there was a
small inhibitory effect of CDK9 S90A (about 20%), but
no effect of CDK9 S90D on basal HIV-1 transcription
(Figure 6A, lanes 1 to 3). In Tat-induced HIV-1 tran-
scription (about 10-fold activation, not shown), the ex-
pression of CDK9 S90A inhibited HIV-1 transcription by
about 60% whereas the expression of CDK S90D acti-
vated HIV-1 transcription nearly 2-fold (Figure 6B, lanes
1 to 3). These results indicate that Ser 90 phosphoryl-
ation may stimulate, and dephosphorylation – inhibitTat-induced HIV-1 transcription. In a control experi-
ment, equal expression levels were observed for WT
CDK9, CDK9 S90A and CDK9 S90D and for co-
expressed cyclin T1 (Figure 6C).
Ser 90 is located on a flexible exposed loop
To visualize Ser90 in the CDK9 structure, residues Ala89-
Lys96 of CDK9 were modeled with ICM-Pro software
package using the coordinates of PDB entry 3MIA [35] as
template. Loop sampling resulted in a set of low-energy
backbone conformations. The subset of conformations
with the lowest energy contains several structures that
AB
CDK9
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Figure 5 Substitution of CDK9 serine 90 for alanine reduces
CDK9 association with large P-TEFb complex. 293T cells were
transfected with Flag-tagged WT CDK9, CDK9 S90A and CDK9 S90D
and also co-transfected with Cyclin T1-expressing vectors. At 48 hrs
posttransfection, the cells were lysed with low salt (large complex –
LC) buffer followed by high salt buffer (small complex – SC). CDK9
expression was analyzed by Western blotting. (A) Representative
immunoblots. (B) Quantification of CDK9 in large (LC) and small
(SC) complexes conducted in two independent experiments.
(C) Co-immunoprecipitation analysis. 293T cells were transfected
with Flag-tagged WT CDK9 and CDK9 S90A and also co-transfected
with Cyclin T1 expressing vectors. At 48 hrs post-transfection, the
cells were lysed; CDK9 was immunoprecipitated from cellular lysates
with anti-Flag antibodies, resolved on 10% SDS PAGE and analyzed
by immunoblotting with antibodies for Hexim1, CDK9 and cyclin T1.
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Figure 6 CDK9 Ser 90 substitutions affect Tat-dependent HIV-1
transcription. (A-B) 293T cells were transfected with HIV-1 LTR-Luc
expression vector along with WT CDK9, CDK9 S90A and CDK9 S90D
expression vectors without (panel A) or with Tat expression vector
(panel B). Cells were lysed at 24 hours posttransfection and
luciferase activity was measured followed by the measurement of
EGFP fluorescence, which was used for the normalization.
Quantification is shown for three independent experiments.
(C) Expression of CDK9 and cyclin T1. To determine the levels of
CDK9 and cyclin T1 expression, 293T cells were transfected with
FLAG-tagged WT CDK9, CDK9 S90A and CDK9 S90D and also
co-transfected with Cyclin T1 and HIV-1 Tat expression vectors. At 48
hrs post-transfection, the cells were lysed, the lysates were resolved
on 10% SDS PAGE and analyzed by immunoblotting with antibodies
for cyclin T1, CDK9, and tubulin was used as loading control. Lane 1,
mock-transfected control.
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Lys96-Asp104 versus Leu81-Thr87 and Ser98-Asp104 in
original PDB), while residues Ser90-Cys95 form flexible
loop. Local energy minimization of side chains was per-
formed for each of these conformations and the structure
with the lowest energy was selected (Figure 7A). The loop
was found to be solvent-exposed and to have no specific
interactions (Figure 7B). Excluding trivial backbone
AB
C Glu 142 Val 8
Figure 7 Modeling of Ser90-containing loop. (A) Structure of
Ser90-containing loop of CDK9 (model based on PDB 3MIA).
Conformation of residues Thr87-Ser98 with the lowest energy.
Backbone representation of residues present in original PDB
structure is shown in blue color. Ser90 is emphasized by thickening.
(B) Structure of CDK9/cyclin T1/Tat complex (model based on PDB
3MIA). Backbone representation of CDK9 residues present in original
PDB structure is shown in blue color. CDK9 Ser90 is shown as balls
and sticks, in red color. Cyclin T1 and Tat are shown in green and
magenta colors respectively. Bullets in cyclin backbone represent
missing residues Lys253-Ala260. (C) Structure of CDK9/cyclin T1/Tat
complex (model based on PDB 3MIA). Backbone representation of
CDK9 residues present in original PDB structure is shown in blue
color. Cyclin T1 and Tat are shown in green and magenta colors
respectively. CDK9 Ser90, CDK9 Val8 and cyclinT1 Gln142 are shown
as balls and sticks, in red, cyan and yellow color, respectively.
Minimal distance between heavy atoms of CDK9 Ser90 and CDK9
Val8 is 11.38 Å; minimal distance between CDK9 Ser90 and cyclin T1
Gln142 is 12.41 Å. Positions of Val 8 and Gln142 are indicated.
Figures were prepared with ICM-Pro software package.
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Ser90 (Figure 7C). The absence of residues Ala89-Lys96 in
all available X-ray structures and the dissimilarity of
several low-energy conformations suggest that this loop is
highly mobile.
Discussion
We have shown here that that CDK2 phosphorylates
CDK9 on Ser90 and that this is important for the induc-
tion of HIV-1 transcription. Our previous studies
showed that HIV-1 transcription is activated by Tat in
the G1 phase, but not in the G2 phase [36,37], suggest-
ing that Tat might function in concert with a host cellfactor that is expressed in G1. We later found that Tat
associates with CDK2/cyclin E [21,22]. Inhibition of CDK2
with siRNA [23] or roscovitin [24] inhibited Tat-induced
HIV-1 transcription and HIV-1 replication. Our current
study supports these earlier observations, and provides a
mechanistic explanation for the effect of CDK2.
We recently showed that iron chelators inhibit CDK2 ac-
tivity and HIV-1 transcription [28,29]. We also observed
that iron chelators inhibit CDK9 activity [28]. The inhib-
ition of CDK9 by iron chelators led to the enticing hypoth-
esis that CDK2 has a direct regulatory effect on CDK9. The
present study supports this notion. We show that a siRNA-
mediated loss of CDK2 is associated with a decreased
CDK9 phosphorylation and activity in cultured cells. CDK9
activity is regulated in part through the association of
CDK9/cyclin T1 with 7SK snRNP. In stress-induced cells,
the CDK9/cyclin T1 complex dissociates from the large
molecular weight P-TEFb complex [7,8]. Similarly, CDK9/
cyclin T1 dissociates from the large-molecular weight P-
TEFb complex when CDK9 is inhibited with flavopiridol
[16]. Interestingly, inhibition of CDK2 resulted in an overall
increase in 7SK RNA levels, and the apparent reduction of
the large P-TEFb complex. The increase in 7SK RNA could
be a compensatory effect to the inability of CDK9 to associ-
ate with large P-TEFb complex. Further study is needed to
investigate the mechanism of 7SK RNA expression and the
effect of CDK2 in this process. The association of CDK9/
cyclin T1 with 7SK snRNP requires the phosphorylation of
CDK9 on Thr186 [30,31]. Dephosphorylation of CDK9 on
Thr186 by protein phosphatase-1 (PP1) disrupts the inter-
action between CDK9/cyclin T1 and 7SK RNA/HEXIM1
in stress-induced cells [38]. Also, protein phosphatase
M1A (PPM1A) was recently shown to dephosphorylate
CDK9 on Thr186 in cultured cells [39,40]. We also recently
showed that expression of an inhibitory fragment of the
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CDK9 on Thr186, and induces the association of CDK9/
cyclin T1 with 7SK RNA, further supporting the notion
that PP1 is needed for the dissociation of CDK9/cyclin T1
from the large P-TEFb complex [41]. Thus, it was logical to
analyze whether Thr186 phosphorylation was affected in
cells with a decreased CDK2 expression. Although we did
not detect changes in Thr186 phosphorylation, the overall
CDK9 phosphorylation was decreased in the CDK2 knock-
down cells, suggesting that different CDK9 residues can be
phosphorylated by CDK2. The T-loop of CDK9 contains
Ser175, the phosphorylation of which, in addition to
Thr186, was shown to affect CDK9 activity [30,31]. Also,
phosphorylation of Thr29 was shown to inhibit CDK9 and
promote the association of CDK9/cyclin T1 with Brd4 [32].
A CDK2 consensus phosphorylation site adheres to
the sequence (S/T)PX(K/R) [34], and is present in CDK9
(S90PYNR94). Phosphorylation of peptides containing
Thr29, Ser175 or Ser90 showed that only Ser90 was
phosphorylated by CDK2. These results were confirmed
with the CDK9 S90A mutant, which was less phosphory-
lated by recombinant CDK2 in vitro and in cultured
cells. Previously, CDK9 was shown to be phosphorylated
on at least ten sites that included Thr186 [30,31], Thr29
[32] and the C-terminal residues Ser329, Thr330,
Thr333, Ser334, Ser347, Thr350, Ser353, and Thr354
[30]. Thus the residual phosphorylation observed with
CDK9 S90A mutant (Figure 4B) can be attributed to one
or several of those sites. We recently showed that
dephosphorylation of the T-loop Ser 175 residue by pro-
tein phosphatase-1 induces CDK9 activity and activates
HIV-1 transcription [33]. We also prepared antibodies
that recognized phosphorylated Ser90, and found that (i)
CDK9 was phosphorylated on Ser90 and (ii) phosphoryl-
ation of Ser90 was decreased after the knockdown of
CDK2. While we were unable to conclude whether
CDK2 KD directly affects formation of the large P-TEFb
complex, CDK9 S90A mutant had a decreased associ-
ation with the large P-TEFb complex. Further analysis is
needed to determine whether CDK2 has a direct effect
on the formation of 7SK snRNP and whether CDK9
Ser90 phosphorylation is involved in this process. Previ-
ously, 7SK RNA knockdown by siRNA led to increased
apoptosis but did not change the expression of P-TEFb
dependent genes including integrated HIV-1 LTR, sug-
gesting that 7SK RNA has an important cellular function
outside of the regulation of cellular or HIV-1 transcrip-
tion. Consistent with this our notion that Ser90 phos-
phorylation is important of HIV-1 transcription
regulation, CDK9 S90D induced Tat-dependent HIV-1
transcription, whereas CDK9 S90A was inhibitory. In
the absence of Tat, both mutants had little effect on
HIV-1 transcription. To understand how Ser 90 phos-
phorylation affects CDK9, we modeled residues 89 to 96,which are not seen in the crystal structure [35]. The
modeling showed that residues Ser 90-Cys 95 form a
flexible loop that is exposed to solvent and has no spe-
cific interactions. One possible explanation for the effect
of Ser 90 phosphorylation may be a conformational
change that may affect the binding of CDK9 and cyclin
T1 to HEXIM1. Future structural and biochemical stud-
ies are needed to analyze the effect of Ser90 phosphoryl-
ation on CDK9 conformation and binding to HEXIM1.
Earlier studies showed that CDK2 activity is required
for the entry into S-phase [42,43] and that the expres-
sion of a dominant-negative CDK2 arrests cells in G1
[44,45]. But because mice lacking CDK2 are viable
[46,47], CDK2 might be redundant for the cell cycle
regulation. In cells that lack CDK2, CDK1 forms func-
tional complexes with cyclin D and cyclin E [48,49].
However, the recent use of chemical genetics by Robert
Fisher and colleagues showed a non-redundant, rate-
limiting role of CDK2 in restriction point passage and
entry into the S-phase [50]. Thus partial knock-down of
CDK2 in the present study might have preserved the
CDK2 function required for the cell cycle progression
and may be used as a strategy for anti-HIV-1 therapeu-
tics. Alternatively, activation of CDK2 can be used as a
strategy to facilitate CDK9 Ser90 phosphorylation and
induce latent HIV-1 provirus. Recently, the CDK9 in-
hibitor flavopiridol was shown to induce apoptosis in
primary chronic lymphocytic leukemia by targeting
CDK9, cyclin T1, AFF3/4 and MLLT1 [51]. Thus, devel-
opment of CDK2 and CDK9 inhibitors may also be use-
ful for the development of cancer drugs.
Conclusion
Taken together, our study has identified Ser90 as a novel
phosphorylation site of CDK9. The phosphorylation of
Ser90 by CDK2 represents a novel mechanism of HIV-1
regulated transcription and provides a new strategy for
activation of latent HIV-1 provirus.
Methods
Materials
293T cells were purchased from ATCC (Manassas, VA).
Histone H1 was purchased from Upstate Cell Signaling
Solutions (Charlottesville, VA). Anti-FLAG monoclonal
antibodies, protein G and protein A agarose were pur-
chased from Sigma (Atlanta, GA). Recombinant CDK2/
cyclin E and CDK9/cyclin T1 were purchased from ProQi-
nase (Freiburg, Germany). Antibodies against CDK9, CDK2
and cyclin T1 were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Anti-CDK9 phospho-Thr186 poly-
clonal antibodies were a kind gift from Dr. Qiang Zhou
(University of California, Berkeley). Preparation of CDK9
Ser 90 phospho-specific antibodies is described below.
Horseradish peroxidase (HRP)-conjugated F(ab)2 fragment
Breuer et al. Retrovirology 2012, 9:94 Page 11 of 15
http://www.retrovirology.com/content/9/1/94was purchased from GE Healthcare (Piscataway, NJ). All
other inorganic reagents were purchased from Fisher Scien-
tific (Fair Lawn, NJ) or Sigma (St. Louis, MO). Radioactive
materials were purchased from Perkin-Elmer (Waltham
MA). ARC (4-Amino-6-hydrazino-7-beta-D-Ribofuranosyl-
7H-Pyrrolo (2,3-d)-pyrimidine-5-Carboxamide) [52] was a
gift from Dr. Andrei L. Gartel (Departments of Medicine,
Microbiology and Immunology, University of Illinois at
Chicago).
Plasmids
The HIV-1 genomic vector, pNL4-3.Luc.R-E- (Courtesy
of Prof. Nathaniel Landau, NYU School of Medicine,
New York, NY) was obtained from the NIH AIDS
Research and Reference Reagent Program. The Tat ex-
pression plasmid was a gift from Dr. Ben Berkhout (Uni-
versity of Amsterdam). WT HIV-1 LTR (−105 to +77)
followed by the luciferase reporter gene (KB SP WT)
was kindly provided by Dr. Manuel López-Cabrera (Uni-
dad de Biología Molecular, Madrid, Spain).
Transfections
293T cells were seeded in 6 well plates to achieve 50%
confluence at the day of transfection. The cells were
transfected with indicated plasmids using Lipofectamine
and Plus reagents (Life Technologies) following manu-
facturer’s protocol. The efficiency of transfection was
verified using a plasmid encoding green fluorescent pro-
tein. The cells were cultured for 48 hrs post-transfection
and then analyzed for HIV-1 transcription or phosphor-
ylation of CDK9.
siRNA transfections
CDK2-directed siRNA (siGENOME SMARTpool reagent
M-003236-03-0005) and a control siRNA (D-001206-13-
05) were purchased from Dharmacon (Dallas, TX). Con-
trol siRNA targets firefly luciferase gene. The siRNAs were
transfected at final concentration of 100 nM using Lipo-
fectamin reagent (Invitrogen) according to the manufac-
turer’s recommendations. The siRNAs were incubated
with cells for 2 days before cells were lysed for Western
blotting analysis or retransfected.
Stable CDK2-knock-down cell line
293T cells were transfected with HSH000225-1-LvH1 vec-
tors expressing shRNA that targeted 399gcttaaggagctttaac-
cat418 (OS211957), 919ccaggagttacttctatgc937 (OS211958),
1010atggacggagcttgttatc1028 (OS211959) and 49aggcggcaa-
cattgtttca67 (OS211960) sequences of CDK2 (GeneCo-
poeia, Rockville, MD). Stable clones were selected with 10
μg/ml puromycin. Several clones transfected with
OS211959 vector showed significant decrease in CDK2
expression and one of these clones, designated as 293T-
CDK KD cells, was used for further studies.HIV-1 Transfections
293T and 293T-CDK KD cells were co-transfected
with pNL4-3 Luc plasmids and CMV-LacZ expression
vector. After 48 hours the cells were collected, washed
in PBS, and lysed with Steady Lite Luciferase. The sam-
ples luminescence was determined in a Luminoskan
Perkin-Elmer). The lysates were then used to measure
β-galactosidase activity with ONPG-based assay [53].
Luciferase activity was normalized on the basis of the
obtained β-galactosidase activity.
HIV-1 Tat activated transcription
293T cells were co-transfected with CDK9 WT and
mutants and KB SP WT. Cells were also co-transfected
with Tat-expressing vector. After 48 hrs the cells were
collected, washed in PBS, lysed with Steady Lite Lucifer-
ase lysis buffer, and luminescence was determined in a
Luminoskan. Luciferase activity was normalized to GFP
expression.
VSVG-HIV-1 Infection
VSVG-HIV-1 was added to 293T and 293T-CDK2 KD
cells that were seeded in 24-well plate at ~30 confluence.
After 48 hours, the cells were washed in PBS, and lysed
with Steady Lite Luciferase buffer. Light emission was
analyzed in a Luminoskan. To adjust for the cell num-
ber, the MTT assay was performed. Control samples
were supplemented with 0.5 mg/ml 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and
incubated for 1 hr at 37°C. Media was removed, forma-
zan crystals were solubilized in dimethyl sulfoxide and
absorbance was measured at 654 nm. Luciferase activity
was normalized for MTT reading at 654 nm.
Analysis of CDK2 mRNA expression
Total RNA was extracted from cultured 293T and 293T-
CDK KD cells using TRIzol reagent according to the manu-
facturer’s protocol (Invitrogen Corp.). Total RNA (100 ng)
was reverse transcribed to cDNA using Superscript™ RT-
PCR kit (Invitrogen, Carlsbad, CA), hexamers and oligo-dT
were used as primers. Real-time PCR analysis was con-
ducted on Roche LightCycler 480 detection system (Roche
Diagnostics) with SYBR Green. The cDNA was amplified
in 45 cycles of denaturation at 95°C for 10 seconds, anneal-
ing at 60°C for 10 seconds, and extension at 72°C for 10
seconds and primers for β-Actin, CDK2, Cyclin A and Cyc-
lin E. Primer sequences for β-Actin, forward-AGGCTC
AGAGCAAGAGAG, reverse-TACATGGCTGGTGTGTT
GA, amplicon size 229; CDK2 forward- TTTGCTGAGA
TGGTGACTCG, reverse- CTTCATCCAGGGGAGGTA
CA, amplicon size 196 bp; Cyclin A, forward-GAAACT
GCAGCTCGTAGGAA, reverse-ACTTTCAGAAGCAAG
TGTTCCA, amplicon size 150bp; Cyclin E, forward –
AGCACTTTCTTGAGCAACACC, reverse-CGCCATAT
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for β-Actin, CDK2, Cyclin A and cyclin E were determined
and expression levels determined using ΔΔCp analysis
using β-Actin as reference. Unpaired t-test was used to test
statistical significance.
Cell cycle analysis of 293T-CDK KD cells
Approximately 1 million cells were fixed in 70% ethanol
at -20°C for 2 hours and stained with Propidium Iodide
(10mg/ml) containing RNAse (1mg/ml) for 30 minutes.
The data were acquired in BD FACSCalibur (BD Bios-
ciences, Jose, California) and analysis was done using
FlowJo software. Unpaired t-test was used to test statis-
tical significance.
Separation of large and small P-TEFb complexes by
differential salt extraction
293T cells, 293T –CDK2 KD cells that stably express
CDK2 shRNA (OS211959) or 293T cells transiently
transfected with a combination of Flag-tagged CDK9
(WT or S90A mutant) and cyclin T1 were cultured in
DMEM containing 10% fetal bovine serum. Cells were
resuspended in Buffer A (10 mM HEPES (pH 7.9), 10
mM KCl, 10 mM MgCl2, 1 mM EDTA, 250 μM sucrose,
1 mM DTT, 0.5% NP-40 and protease inhibitors) added
at 500 μl/107 cells. The mixture was incubated on ice for
10 min and centrifuged at 1000 x g for 5 min to pellet
the nucleus. The supernatant was removed and saved as
the large complex extract (LC). The remaining pellet
was resuspended in Buffer B (20 mM HEPES-KOH (pH
7.9), 450 mM NaCl, 1.5 mM MgCl2, 0.5mM EDTA, 1
mM DTT and protease inhibitors) added at 500 μl/107
cells. The mixture was incubated on ice for 10 min and
centrifuged at 10,000 x g for 1 hr. The supernatant was
saved as the small complex extract (SC) (11). The LC
and SC were resolved by SDS-PAGE and transferred to
a PVDF membrane (Millipore, Allen, TX) for Western
blotting. The membrane was probed with anti-CDK9
antibodies.
Immunoprecipitations
293T cells were lysed in whole cell lysis buffer (50 mM
Tris–HCl, pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS)
supplemented with protease cocktail. CDK9 was precipi-
tated as indicated with either anti-CDK9 antibodies or
anti-Flag antibodies in the case of overexpression of
Flag-CDK9 as we previously described [33]. Briefly, 400
μg of lysate and 800 ng of antibodies combined with 50
μl of 50% slurry of protein A/G agarose were incubated
for 2 hrs at 4°C in a TNN Buffer (50 mM Tris–HCl, pH
7.5, 150 mM NaCl and 1% NP-40). The agarose beads
were precipitated and washed with TNN buffer, reso-
lved on 10% Tris-Glycine SDS-PAGE, transferred topolyvinylidene fluoride (PVDF) membranes and immu-
noblotted with appropriate antibodies.
RT-PCR to detect 7SK RNA
RNA was isolated from complexes that co-immunoprecipitated
with anti-CDK9 antibodies or nonspecific IgG as controls
using TRIzol reagent according the Invitrogen’s protocol.
RNA was also extracted from total cell extract or small
and large complex extracts prepared as described above.
Total RNA was reverse transcribed using SuperScript II
kit (Invitrogen) with the 7SK reverse primer. The follow-
ing primer sequences were used: forward primer 30-
GGATGTGAGGCGATCTGGCTG-50; reverse primer
30-TAAAGAAAGGCAGACTGCCAC-50. Theses pri-
mers were used in a PCR reaction that followed the RT
reaction. Real-time PCR analysis was conducted on
Roche LightCycler 480 detection system (Roche Diag-
nostics) with SYBR Green. The cDNA was amplified in
45 cycles of denaturation at 95°C for 10 seconds, anneal-
ing at 60°C for 10 seconds, and extension at 72°C for 10
seconds. To quantify the amount of 7SK RNA, serial dilu-
tions of 7SK RNA expressing vector [54] was used to de-
termine the copy number. For ΔΔ Cp analysis of 7SK
RNA in small and large complex extracts, RNA was re-
verse transcribed with hexamers and U6 RNA was used
as reference. In semi-quantitative PCR, 7SK RNA was
amplified for 30 cycles, resolved on 2% agarose gel and
photographed.
CDK9 kinase assay
Kinase assay was performed at 30°C for 30 min in a kin-
ase assay buffer (50 mM HEPES-KOH, pH 7.9, 10 mM
MgCl2, 6 mM EGTA, 2.5 mM DTT) containing 100 ng
of GST-CTD as substrate, 200 μM cold ATP and 5 μCi
of (γ-32P) ATP. Kinase reactions were stopped with
SDS-loading buffer and resolved on 10% PAGE. The
dried gel was exposed to Phosphor Imager screen.
CDK2 phosphorylation assay
293T and 293T-59 cells were lysed in whole cell lysis
buffer (50 mM Tris–HCl, pH 7.5, 0.5 M NaCl, 1% NP-
40, 0.1% SDS) supplemented with protease cocktail.
CDK2 was precipitated with anti-CDK2 antibodies as
described above. Kinase assay was performed at 30°C for
20 min in the kinase assay buffer containing 2 μg
Histone H1 as substrate, 200 μM cold ATP and 5 μCi of
(γ-32P) ATP. Kinase reactions were stopped with SDS-
loading buffer and resolved on 10% PAGE. The dried gel
was exposed to Phosphor Imager screen.
Phosphorylation of CDK9-derived peptides
We designed synthetic peptides containing CDK9
residues Thr29 (21KLAKIGQGTFGEVFK35), Ser90
(88KASPYNRCKGSIYL101); and Ser175 and Thr186
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phosphorylated by recombinant CDK2/cyclin E in a 10
μl reaction with 100 μM ATP (1μCi of γ-(32P) ATP) in
the kinase assay buffer using 4 μg of a peptide per reac-
tion for 20 min at 30°C. The reaction was stopped by
the addition of 4X SDS-PAGE loading buffer and
resolved on a 15% Tris-Tricine gel. The gel was stained
with Coomassie blue for 10 min, destained for 1 hr,
dried, and exposed to Phosphor Imager screen.
Constructing CDK9 S90 mutants
QuikChange XL Site-Directed Mutagenesis Kit (Strata-
gene) was used to generate mutants of CDK9 with the
substitutions in the sites of CDK2 phosphorylation
determined previously. Primers for S90A substitution
were GATTTGTCGAACCAAAGCTGCCCCCTATAA
CCGCTGC (forward) and GCAGCGGTTATAGGGG
GCAGCTTTGGTTCGACAAATC (reverse); and for
S90D substitution - GATTTGTCGAACCAAAGCTGAC
CCCTATAACCGCTGC (forward) and GCAGCGGTT
ATAGGGGTCAGCTTTGGTTCGACAAATC (reverse).
CDK9 S90D was created to mimic phosphorylation. PCR
reactions were run for 18 cycles with the extension time
of 8 min to allow the synthesis of the whole plasmid se-
quence. PCR products were digested with Dpn I to de-
grade the original template. The PCR products were
transformed into XL-Gold cells. Colonies were then
picked, and mini preparations were isolated using High
Pure Plasmid Isolation kit (Roche Applied Sciences).
The obtained clones were sequenced. CDK9 mutants
were expressed in 293T cells, immunoprecipitated with
anti-FLAG or anti-Cyclin T1 antibodies and tested for
phosphorylation of GST-CTD as described above.
CDK9 Ser 90 phospho-specific antibodies
CDK9-derived 86 RTKASPYNR94 peptide without or
with Ser 90 phosphorylated was synthesized with an
additional Cys residue at the N-terminus for coupling to
Keyhole limpet hemocyanin (KLH) or BSA. The KLH-
coupled phospho-peptide was injected in the rabbit. The
polyclonal serum was double affinity- purified on the
BSA-coupled phospho- and non-phosphopeptide linked
to CNBr-activated Sepharose-4B (GE Healthcare).
Modeling
The 8 amino acid residues of CDK9, Ala89-Lys96, that
were missing in the CDK9 crystal structure [35], were
modeled with ICM-Pro software package [55,56], version
3.6-1i (Molsoft LLC, 2010). First, missing residues were
built with the ICM homology modeling tool, using
CDK9_HUMAN sequence (Swiss-Prot accession number
P50750) and coordinates of PDB entry 3MIA [35] as
template. Next, conformation sampling of residues
Thr87-Ser98 was performed by ICM ShakeLoop toolusing ICM loop database and a set of low-energy back-
bone conformations was obtained. Finally, local energy
minimization of side chains by biased probability Monte
Carlo procedure provided conformation with the lowest
energy.
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